Phase 3 clinical trials

Significant topical efficacy with once-daily dosing plus extended remission 4 weeks post treatment1,2

Patients with treatment success* (8 week primary endpoint)
Trial 1 8 weeks: 36% treatment success with DUOBRII Lotion vs 7% with vehicle. Trial 2 8 weeks: 45% treatment success with DUOBRII Lotion vs 13% with vehicle Trial 1 8 weeks: 36% treatment success with DUOBRII Lotion vs 7% with vehicle. Trial 2 8 weeks: 45% treatment success with DUOBRII Lotion vs 13% with vehicle
Study design
Hal holding picture of a patient with plaque psoriasis
Superior clearance at primary endpoint in both trials (P<0.001%)2

Only topical combination for psoriasis with proven remission data2

*Treatment success was defined as at least a 2-grade improvement from baseline in Investigator's Global Assessment (IGA) score, and a score of “clear” or “almost clear” (primary endpoint at week 8).1
 
Taz holding picture of a patient with plaque psoriasis

Phase 2 clinical trial

At week 2, patients using DUOBRII Lotion achieved similar clearance to Ultravate cream, with less steroid exposure7

Efficacy results observed in a 2-week QD study
Overall treatment success (IGA: 33% treatment success with DUOBRII Lotion vs 34% with vehicle) 2-grade improvement in signs of psoriasis (Erythema: 34% treatment success with DUOBRII Lotion vs 43% with vehicle; Plaque elevation: 54% treatment success with DUOBRII Lotion vs 51% with vehicle; Scaling: 61% treatment success with DUOBRII Lotion vs 51% with vehicle) Overall treatment success (IGA: 33% treatment success with DUOBRII Lotion vs 34% with vehicle) 2-grade improvement in signs of psoriasis (Erythema: 34% treatment success with DUOBRII Lotion vs 43% with vehicle; Plaque elevation: 54% treatment success with DUOBRII Lotion vs 51% with vehicle; Scaling: 61% treatment success with DUOBRII Lotion vs 51% with vehicle)
Patients were exposed to 400% more corticosteroid with Ultravate cream than with DUOBRII Lotion7
Study design
§Treatment success was defined as at least a 2-grade improvement from baseline in the IGA score, and a score of “clear” or “almost clear” (primary endpoint at week 2)7

QD = once daily
Patients were exposed to 400% more corticosteroid with Ultravate cream than with DUOBRII Lotion7
Hal and Taz high-fiving
See the difference
See the difference

Post hoc analysis of an open-label, long-term safety study

Extended remission seen up to 3 months post treatment6

Percent of patients with a baseline BSA of 3%-12% who achieved and also maintained treatment success‡
1 month post treatment: 55%
2 months post treatment: 28%
3 months post treatment: 19%
Hal and Taz walking side-by-side with Hal holding a daily calendar and pages blowing away behind him
Adverse events seen in a long-term safety study through
8 weeks were consistent with those seen in the phase 3 studies
  • Rate of epidermal atrophy during the long-term study was 0.7%
  • The percentage of subjects with reported adverse events at 8 weeks did not increase throughout the rest of the study (52 weeks)
  • Some individuals may experience atrophy, striae, telangiectasias, and folliculitis.
    If these effects occur, discontinue until the integrity of the skin has been restored

‡Treatment success was defined as at least a 2-grade improvement from baseline in the IGA score, and a score of “clear” or “almost clear”. Retreatment occurred when IGA was at 2-mild. Patients achieved treatment success at any point during the study.6

Study design

See More

Indication

DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, is indicated for the topical treatment of plaque psoriasis in adults.

Important Safety Information

Contraindication

DUOBRII Lotion is contraindicated in pregnancy.

Warnings and Precautions
  • Women of child-bearing potential should be warned of the potential risk of fetal harm from DUOBRII and use adequate birth-control. A negative result for pregnancy should be obtained within 2 weeks prior to treatment. If the patient becomes pregnant during treatment, discontinue DUOBRII Lotion and advise patient of the potential hazard to the fetus.
  • DUOBRII Lotion has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis during or after treatment and may require that patients be evaluated periodically during treatment.
  • Predisposing factors for HPA axis suppression include: use of more potent corticosteroids, use on large areas, use under occlusive dressings, use on altered skin barrier, concomitant use of other steroids, liver failure and young age.
  • Systemic effects of topical corticosteroids may also include Cushing’s syndrome, hyperglycemia, and glucosuria.
  • Local adverse reactions may include atrophy, striae, telangiectasias, folliculitis and contact dermatitis. If these effects occur, discontinue until the integrity of the skin has been restored. Do not resume treatment if contact dermatitis is identified. DUOBRII Lotion should not be used on eczematous skin, as it may cause severe irritation.
  • Avoid exposure to sunlight, sunlamps and weather extremes. Patients with sunburn should be advised not to use DUOBRII Lotion until fully recovered. DUOBRII Lotion should be administered with caution if the patient is also taking drugs known to be photosensitizers because of the increased potential for photosensitivity.
  • Topical corticosteroids may increase the risk of cataracts and glaucoma; advise patients to report any visual symptoms and refer to an ophthalmologist if needed.
Adverse Events
  • The most common adverse events in clinical trials were contact dermatitis (7%), application site pain (3%), folliculitis (2%), skin atrophy (2%), and excoriation (2%).

To report SUSPECTED ADVERSE REACTIONS, contact Ortho Dermatologics at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please click here for full Prescribing Information.

References: 1. DUOBRII Lotion [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC. 2. Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287-293. 3. Kircik LH, Papp KA, Gold LS, Harris S, Lin T, Pillai R. Assessing the synergistic effect of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2019;18(3):279-284. 4. Sugarman JL, Gold LS, Lebwohl MG, et al. A phase 2, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis. J Drugs Dermatol. 2017;16(3):611-618. 5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659. 6. Data on file. 7. Bhatia N, Pariser D, Kircik L, et al. Safety and efficacy of a halobetasol 0.01%/tazarotene 0.045% fixed combination lotion in the treatment of moderate-to-severe plaque psoriasis: a comparison with halobetasol propionate 0.05% cream. J Clin Aesthet Dermatol. 2018;11(11):15-19.

DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045% logo
LinkedIn logo Follow us
on LinkedIn
© 2021 Ortho Dermatologics' affiliated entities. DUO.0318.USA.20V2.0
CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION
DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045% logo
 

Indication

Important Safety Information

See More

DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, is indicated for the topical treatment of plaque psoriasis in adults.

Important Safety Information

Contraindication

DUOBRII Lotion is contraindicated in pregnancy.

DUOBRII Lotion is contraindicated in pregnancy.